Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
•
MGUS
Do you perform biomarker-based screening for AL amyloidosis in patients with newly diagnosed MGUS?
If so, what is your approach to laboratory and clinical testing?
Answer from: Medical Oncologist at Academic Institution
No, unless the patient has signs and symptoms or imaging studies that suggest systemic Amyloidosis.
Sign in or Register to read more
6586
Related Questions
How would you approach the treatment of an elderly patient with multiple myeloma and CALR+ myelofibrosis with elevated platelets?
With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
How do you discuss harms of MGUS screening with other medical providers?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
What is your approach to MRD testing in the frontline treatment of multiple myeloma?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
How would you approach IgM kappa MGUS paraproteinemia with a rising free light chain ratio?